John T Leppert1, Janet Hanley2, Todd H Wagner3, Benjamin I Chung4, Sandy Srinivas5, Glenn M Chertow5, James D Brooks4, Christopher S Saigal6. 1. Department of Urology, Stanford University School of Medicine, Stanford, CA; Veterans Affairs Palo Alto Healthcare System, Palo Alto, CA. Electronic address: jleppert@stanford.edu. 2. Rand Corporation, Santa Monica, CA. 3. Veterans Affairs Palo Alto Healthcare System, Palo Alto, CA; Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA. 4. Department of Urology, Stanford University School of Medicine, Stanford, CA. 5. Department of Medicine, Stanford University School of Medicine, Stanford, CA. 6. Department of Urology, University of California, Los Angeles School of Medicine, Los Angeles, CA; Department of Health Services, University of California, Los Angeles School of Medicine, Los Angeles, CA.
Abstract
OBJECTIVE: To examine the patient, tumor, and temporal factors associated with receipt of renal mass biopsy (RMB) in a contemporary nationally representative sample. METHODS: We queried the Surveillance, Epidemiology, and End Results-Medicare data set for incident cases of renal cell carcinoma diagnosed between 1992 and 2007. We tested for associations among receipt of RMB and patient and tumor characteristics, type of therapy, and procedure type. Temporal trends in receipt of RMB were characterized over the study period. RESULTS: Approximately 1 in 5 (20.7%) patients diagnosed with renal cell carcinoma (n = 24,702) underwent RMB before instituting therapy. There was a steady and modest increase in RMB utilization, with the highest utilization (30%) occurring in the final study year. Of patients who underwent radical (n = 15,666) or partial (n = 2211) nephrectomy, 17% and 20%, respectively, underwent RMB in advance of surgery. Sixty-five percent of patients who underwent ablation (n = 314) underwent RMB before or in conjunction with the procedure. Roughly half of patients (50.4%) treated with systemic therapy alone underwent RMB. Factors independently associated with use of RMB included younger age, black race, Hispanic ethnicity, tumor size <7 cm, and metastatic disease at presentation. CONCLUSION: At present, most patients who eventually undergo radical or partial nephrectomy do not undergo RMB, whereas most patients who eventually undergo ablation or systemic therapy do. The optimal use of RMB in the evaluation of kidney tumors has yet to be determined. Published by Elsevier Inc.
OBJECTIVE: To examine the patient, tumor, and temporal factors associated with receipt of renal mass biopsy (RMB) in a contemporary nationally representative sample. METHODS: We queried the Surveillance, Epidemiology, and End Results-Medicare data set for incident cases of renal cell carcinoma diagnosed between 1992 and 2007. We tested for associations among receipt of RMB and patient and tumor characteristics, type of therapy, and procedure type. Temporal trends in receipt of RMB were characterized over the study period. RESULTS: Approximately 1 in 5 (20.7%) patients diagnosed with renal cell carcinoma (n = 24,702) underwent RMB before instituting therapy. There was a steady and modest increase in RMB utilization, with the highest utilization (30%) occurring in the final study year. Of patients who underwent radical (n = 15,666) or partial (n = 2211) nephrectomy, 17% and 20%, respectively, underwent RMB in advance of surgery. Sixty-five percent of patients who underwent ablation (n = 314) underwent RMB before or in conjunction with the procedure. Roughly half of patients (50.4%) treated with systemic therapy alone underwent RMB. Factors independently associated with use of RMB included younger age, black race, Hispanic ethnicity, tumor size <7 cm, and metastatic disease at presentation. CONCLUSION: At present, most patients who eventually undergo radical or partial nephrectomy do not undergo RMB, whereas most patients who eventually undergo ablation or systemic therapy do. The optimal use of RMB in the evaluation of kidney tumors has yet to be determined. Published by Elsevier Inc.
Authors: Marta E Heilbrun; Junhua Yu; Kenneth J Smith; Christopher B Dechet; Ronald J Zagoria; Mark S Roberts Journal: J Urol Date: 2011-11-16 Impact factor: 7.450
Authors: Schuyler J Halverson; Lakshmi P Kunju; Ritu Bhalla; Adam J Gadzinski; Megan Alderman; David C Miller; Jeffrey S Montgomery; Alon Z Weizer; Angela Wu; Khaled S Hafez; J Stuart Wolf Journal: J Urol Date: 2012-12-14 Impact factor: 7.450
Authors: Michael J Leveridge; Antonio Finelli; John R Kachura; Andrew Evans; Hannah Chung; Daniel A Shiff; Kimberly Fernandes; Michael A S Jewett Journal: Eur Urol Date: 2011-06-24 Impact factor: 20.096
Authors: Alessandro Volpe; Antonio Finelli; Inderbir S Gill; Michael A S Jewett; Guido Martignoni; Thomas J Polascik; Mesut Remzi; Robert G Uzzo Journal: Eur Urol Date: 2012-05-12 Impact factor: 20.096
Authors: Patrick O Richard; Lisa Martin; Luke T Lavallée; Philippe D Violette; Maria Komisarenko; Andrew J Evans; Kunal Jain; Michael A S Jewett; Antonio Finelli Journal: Can Urol Assoc J Date: 2018-04-06 Impact factor: 1.862
Authors: Jeremiah J Morrissey; Vincent M Mellnick; Jingqin Luo; Marilyn J Siegel; R Sherburne Figenshau; Sam Bhayani; Evan D Kharasch Journal: JAMA Oncol Date: 2015-05 Impact factor: 31.777
Authors: Andrew W Silagy; Alejandro Sanchez; Brandon J Manley; Karim Bensalah; Axel Bex; Jose A Karam; Börje Ljungberg; Brian Shuch; A Ari Hakimi Journal: Eur Urol Focus Date: 2019-04-28
Authors: Joel Prince; Eric Bultman; Louis Hinshaw; Anna Drewry; Michael Blute; Sara Best; Fred T Lee; Timothy Ziemlewicz; Meghan Lubner; Fangfang Shi; Stephen Y Nakada; E Jason Abel Journal: J Urol Date: 2014-12-11 Impact factor: 7.450